Adial holds 2026 annual meeting, adjourns vote on four proposals pending Nasdaq approval

Adial Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders on September 17, 2026, according to an 8-K filed with the SEC. A quorum was present, with 1,278,677 shares, or 48.7% of the 2,625,890 shares of Common Stock outstanding, present or represented by proxy.¹

All twelve proposals on the agenda received strong preliminary support, but the company held off on completing votes for Proposals 3, 4, 5 and 6 because Nasdaq had not yet granted conditional approval of an Initial Listing Application tied to those items.¹ Polls remain open for those four proposals, and the adjourned session is set to reconvene on October 1, 2026 at 8:30 a.m. Eastern Time at the company's Charlottesville, Virginia offices.¹ The record date for the meeting, as adjourned, stays at August 17, 2026.¹

Among the proposals finalized on September 17, stockholders elected Cary J. Claiborne and Robertson H. Gilliland as Class II directors to serve until the 2029 Annual Meeting¹, though both are expected to resign shortly after all proposals in the Definitive Proxy Statement gain approval.¹

Stockholders also ratified CBIZ CPAs P.C. (formerly Marcum, LLP) as the company's independent registered public accounting firm for fiscal year 2026¹, approved raising authorized common shares from 100,000,000 to 500,000,000¹, and approved issuance of up to 552,940 shares tied to Series F warrants from a private placement that closed on November 28, 2025.¹ They further approved amendments to the 2017 Equity Incentive Plan, a new 2026 Equity Incentive Plan, and a 2026 Employee Stock Purchase Plan.¹